Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Who Will Replace Jensen Huang? Here's What Prediction Markets Think.

Key PointsJensen Huang stepped down as CEO of Nvidia, with CFO Colette Kress taking over in the interim.

Nvidia co-founder and CEO Jensen Huang resigned on November 12, leading to speculation about who will replace him. Prediction market platform Kalshi provides insight into potential successors. Ian Buck, Nvidia's vice president of hardware systems, leads the field with a 36% implied probability of becoming CEO. Buck's expertise in GPU programming through CUDA makes him a strong candidate, especially with hyperscalers driving most AI infrastructure investments.

Nvidia's CFO, Colette Kress, has a 19% chance of taking the helm, currently serving as interim CEO. Former Arm CEO Rene Haas, with 10% odds, brings semiconductor design experience to the table. Former Apple CEO Tim Cook has 4% odds, though his candidacy appears speculative. While prediction markets offer insights, they are subject to change based on trading activity and liquidity.

Nvidia's next CEO will lead a company with significant competitive advantages, including Blackwell and Vera Rubin computing platforms, proprietary networking tech, and CUDA software. Investors should focus on Nvidia's execution of its technology roadmap rather than fluctuating market odds or rumors.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Labcorp: 3 Key Takeaways for Long-Term Investors

Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.

  • Labcorp reported 7% revenue growth to $3.8 billion for Q3 2026
  • PAMA will lower Medicare reimbursement rates in 2027, estimated $125M hit
  • Strategic acquisitions of BioReference, Myriad Genetics and Millennium Health

More from Friday 13 November →